<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1162">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392531</url>
  </required_header>
  <id_info>
    <org_study_id>FJD-COVID19-20-01</org_study_id>
    <nct_id>NCT04392531</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19</brief_title>
  <official_title>Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that cyclosporine, added to standard treatment of hospitalized
      patients with COVID19 infection may improve their prognosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity Category</measure>
    <time_frame>12 days</time_frame>
    <description>efficacy of the association of CsA with standard treatment in reducing the severity of COVID19 infection in hospitalized patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>efficacy of CsA in combination with standard treatment in reducing mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days in hospital</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>efficacy of CsA in combination with standard treatment in reducing days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in ICU beds</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>efficacy of CsA in combination with standard treatment in reducing days in ICU beds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fio2 Needs</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>efficacy of CsA in combination with standard treatment in reducing FiO2 needs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events rate</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>safety and tolerability of cyclosporine vs standard treatment administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP</measure>
    <time_frame>every 48 hours from randomization until patient discharge, and at the end of study visit (14 days after discharge or 14 days after end of study treatment, depending of what applies)</time_frame>
    <description>change from baseline in C reactive protein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ferritin</measure>
    <time_frame>every 48 hours from randomization until patient discharge, and at the end of study visit (14 days after discharge or 14 days after end of study treatment, depending of what applies)</time_frame>
    <description>change from baseline in ferritin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDH</measure>
    <time_frame>every 48h during hospitalization and end of study visit (14 days after discharge or 14 days after end of study treatment)</time_frame>
    <description>change from baseline in LDH levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CPK</measure>
    <time_frame>every 48 hours from randomization until patient discharge, and at the end of study visit (14 days after discharge or 14 days after end of study treatment, depending of what applies)</time_frame>
    <description>change from baseline in Creatin phosphokinase levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D Dimer</measure>
    <time_frame>every 48 hours from randomization until patient discharge, and at the end of study visit (14 days after discharge or 14 days after end of study treatment, depending of what applies)</time_frame>
    <description>change from baseline in D Dimer levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IL-6</measure>
    <time_frame>Days 1, 8, 15 and end of study visit (14 days after discharge or 14 days after end of study treatment)</time_frame>
    <description>change from baseline in IL-6 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in KL-6</measure>
    <time_frame>Days 1, 8, 15 and end of study visit (14 days after discharge or 14 days after end of study treatment)</time_frame>
    <description>change from baseline in KL-6 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Viral Load</measure>
    <time_frame>Days 1,8,15 and end of study visit (14 days after discharge or 14 days after end of study treatment)</time_frame>
    <description>COVID19 Viral load determination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change specific antibodies</measure>
    <time_frame>Days 1,8,15 and end of study visit (14 days after discharge or 14 days after end of study treatment)</time_frame>
    <description>Specific IgG and IgM determination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COVID19 Infection</condition>
  <arm_group>
    <arm_group_label>Group A (control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will consist on the standard treatment that patients will receive according to hospital standard of care protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will consist on cyclosporine added to the standard treatment that patients will receive according to hospital standard of care protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)</description>
    <arm_group_label>Group B (experimental)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Standard of care according to hospital protocol</description>
    <arm_group_label>Group A (control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women and men over 18 years old

          2. Clinical diagnosis of COVID19 infection (to be subsequently confirmed by PCR or
             specific IgM isotype Ac and with entry criteria according to the protocol of action
             (see Annex 2)

          3. Acceptance and signing of the consent for the study after having received the
             appropriate information.

        Exclusion criteria

          1. Known allergy or hypersensitivity to any of the medications included in the treatment
             arms or to any of their components.

          2. Contraindication for the use of any of the medications included (*)

               -  CsA: IR EST 4.5 (FG &lt;30 ml / min according to the Cockcroft-Gault formula)

               -  Antimalarials (Chloroquine, hydroxychloroquine): Retinopathy, Myasthenia gravis.

               -  Lopinavir / ritonavir: severe liver failure

               -  Remdesivir, darunovir-ritonavir

               -  Doxycycline, Azithromycin

          3. Kidney failure (Stages 4 and 5: GFR &lt;30 ml / min according to the cockcroft-Gault
             formula).

          4. Decompensated liver disease (Child-Pugh stages B or C) or chronic infection with virus
             B

          5. Pregnancy or lactation

          6. Age over 75 years

          7. Participants in another clinical trial with medication in the 28 days prior to the
             start of recruitment. Participation in observational studies is allowed.

          8. Refusal to participate

          9. Patient with a poor state of health or nutrition who, in the opinion of the
             researcher, has sufficient criteria of severity to interfere with the development of
             the study or its conclusions

         10. At the investigator's discretion, the patient's inability to understand or comply with
             the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Sanchez Pernaute, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FUNDACION JIMENEZ DIAZ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga Sanchez Pernaute, MD, PhD</last_name>
    <phone>0034915504800</phone>
    <phone_ext>3218</phone_ext>
    <email>osanchez@fjd.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucia Llanos Jimenez, MD, PhD</last_name>
    <phone>0034915504800</phone>
    <phone_ext>3214</phone_ext>
    <email>lucia.llanos@fjd.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario La Coruña</name>
      <address>
        <city>La Coruña</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>FRANCISCO J BLANCO GARCIA, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron La Coruña</name>
      <address>
        <city>La Coruña</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>HECTOR MEJIDE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Rey Juan Carlos</name>
      <address>
        <city>Mostoles</city>
        <state>Madrid</state>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIREIA ARCAS TOMEO, BSc</last_name>
      <email>mireia.arcas@fjd.es</email>
    </contact>
    <investigator>
      <last_name>IGNACIO ROBLES BARRENA, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>CELIA ZAMARRO GARCIA, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Elena</name>
      <address>
        <city>Valdemoro</city>
        <state>Madrid</state>
        <zip>28342</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIREIA ARCAS TOMEO, BSc</last_name>
      <email>mireia.arcas@fjd.es</email>
    </contact>
    <investigator>
      <last_name>FRANCISCO JAVIER RUIZ HORNILLOS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ANGEL JIMENEZ RODRIGUEZ, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARCO ANTONIO CASTILLO, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Villalba</name>
      <address>
        <city>Villalba</city>
        <state>Madrid</state>
        <zip>28400</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIREIA ARCAS TOMEO, BSc</last_name>
      <email>mireia.arcas@fjd.es</email>
    </contact>
    <investigator>
      <last_name>M JESUS RODRIGUEZ NIETO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>GLORIA PINDAO QUESADA, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>PATRICIA MILAGROS LAZO MENESES, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIREIA ARCAS TOMEO, BSc</last_name>
      <phone>0034915504800</phone>
      <phone_ext>3214</phone_ext>
      <email>mireia.arcas@fjd.es</email>
    </contact>
    <investigator>
      <last_name>Olga Sanchez Pernaute, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beatriz Alvarez Alvarez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolina Maria Gotera Rivera, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>German Peces-Barba Romero, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Gorgolas Hernandez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfonso Cabello Ubeda, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cesar Perez Calvo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Heili Frades, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fredeswinda Romero Bueno, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucia Llanos Jiménez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nerea Carrasco Antón, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MABEL FIOL PIQUERO</last_name>
    </contact>
    <investigator>
      <last_name>LUIS SEIJO MACEIRAS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

